RxDoctor Payments DataLook up a doctor →

Thomas Lomis, MD

Surgical Oncology · van Nuys, CANPI 1023037199

Payments from drug & device makers

$611,956in general payments, 2019–2025

Across 217 payments — averaging $2820.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$578K
  • AstraZeneca$28K
  • GE HealthCare$2K
  • Ipsen Biopharmaceuticals, Inc$247
  • Intuitive Surgical$229
  • Karyopharm Therapeutics Inc.$198
  • plus $4K from 54 others
$943in research payments, 2019–2025

Across 2 payments — averaging $471.48 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$943

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis26$577,795
AstraZeneca(2 entities)16$27,820
GE HealthCare3$2,038
Ipsen Biopharmaceuticals, Inc10$247
Intuitive Surgical4$229
Karyopharm Therapeutics Inc.7$198
Bayer11$180
Regeneron Healthcare Solutions, Inc.6$174
Pfizer6$172
Progenics Pharmaceuticals, Inc.2$154
Amgen7$153
Incyte Corporation6$142
Merck7$142
Lilly USA, LLC6$140
Johnson & Johnson(2 entities)6$138
Genentech USA, Inc.6$129
Puma Biotechnology, Inc.6$126
Seagen Inc.7$112
GSK4$107
Philips North America LLC1$103
Tesaro, Inc.4$103
Sobi, Inc3$90
Eisai Inc.4$83
Takeda Pharmaceuticals U.S.A., Inc.3$82
Sanofi4$76
Taiho Oncology, Inc.3$72
Boehringer Ingelheim4$71
Leica Microsystems Inc.2$68
Blueprint Medicines Corporation3$65
Stemline Therapeutics Inc.2$58
Fennec Pharmaceuticals, Inc.3$58
Tersera Therapeutics LLC2$57
Boston Scientific1$55
Daiichi Sankyo Inc.2$51
Jazz Pharmaceuticals Inc.2$47
Kyowa Kirin, Inc.2$40
Agios Pharmaceuticals, Inc.2$38
Pharmacosmos Therapeutics Inc.1$38
Baxter Healthcare1$35
Gilead1$34
Genmab U.S., Inc.1$33
Coherus Oncology, Inc.1$29
Heron Therapeutics, Inc.2$28
Blue Earth Diagnostics1$27
Medtronic1$26
Tempus AI, Inc1$25
Sun Pharmaceutical Industries Inc.1$24
Deciphera Pharmaceuticals Inc.1$23
Curium US LLC1$23
Telix Pharmaceuticals1$22
Pharmaessentia USA Corporation1$22
CTI Biopharma Corp.1$22
G1 Therapeutics, Inc.1$19
Epizyme, Inc.1$18
Tolmar Pharmaceuticals, Inc.1$18
Iovance Biotherapeutics, Inc.1$18
AVEO Pharmaceuticals, Inc.1$16
TELA Bio, Inc.1$16
Morphosys, US Inc.1$16
Novocure Inc.1$13

How this compares

$611,956 in reported general payments places this provider in the 95th percentile of 209 surgical oncology providers in California.

See all surgical oncology providers in California →

Medicare billing

Part B allowed, 2024
$72,394
Medicare patients
210
Services billed
497

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other surgical oncology in van Nuys

See the full list for California →

Where these figures come from

Is this you, or does something look wrong? →